Loading...
•
Sep 30, 2024
4DMT Q3 2024 Earnings Report
Reported third quarter financial results and provided operational highlights.
Key Takeaways
4DMT reported positive interim data for 4D-150 in wet AMD and is on track with the 4FRONT Phase 3 program. The company's cash, cash equivalents, and marketable securities were $551 million as of September 30, 2024, expected to fund planned operations at least into H1 2027.
Presented positive interim data for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial.
4D-150 4FRONT Phase 3 program in wet AMD continues to be on track with 4FRONT-1 trial initiation expected in Q1 2025.
Company product portfolio strategy and cash utilization updates, together with SPECTRA clinical trial program and interim data updates in diabetic macular edema (DME), expected in early January 2025.
Cash, cash equivalents and marketable securities were $551 million as of September 30, 2024, expected to fund planned operations at least into H1 2027.
4DMT
4DMT
Forward Guidance
4DMT anticipates several milestones in the near future.
Positive Outlook
- 52-week interim data from Phase 2b cohort of PRISM clinical trial expected in February 2025.
- 4FRONT-1 Phase 3 clinical trial initiation expected in Q1 2025.
- SPECTRA clinical trial program and interim data updates expected in early January 2025.
- Phase 1 enrollment for 4D-175 for Geographic Atrophy expected to begin in Q1 2025.
- Interim data and program update from AEROW clinical trial is expected in mid-2025.